U Brinkmann

Summary

Affiliation: EPIDAUROS Biotechnologie AG
Country: Germany

Publications

  1. ncbi Recombinant antibody fragments and immunotoxin fusions for cancer therapy
    U Brinkmann
    Epidauros Biotechnology, Pharmacogenetics Laboratory, Bernried, Germany
    In Vivo 14:21-7. 2000
  2. ncbi Polymorphisms in the ABC drug transporter gene MDR1
    U Brinkmann
    Epidauros Biotechnology, Pharmacogenetics Labs, Bernried, Germany
    Pharmacogenomics J 1:59-64. 2001
  3. ncbi Recombinant immunotoxins for cancer therapy
    U Brinkmann
    Epidauros Biotechnology, Pharmacogenetics Lab, Bernried, FRG, Germany
    Expert Opin Biol Ther 1:693-702. 2001
  4. ncbi ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2
    R Kerb
    Epidauros Biotechnology, Pharmacogenetics Laboratory, Am Neuland 1, D 82347 Bernried, Germany
    Pharmacogenomics 2:51-64. 2001
  5. ncbi The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels
    R Kerb
    Epidauros Biotechnology AG, Pharmacogenetics Laboratory, Bernried, Germany
    Pharmacogenomics J 1:204-10. 2001
  6. ncbi Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4
    E Hustert
    EPIDAUROS Biotechnologie AG, Bernried, Germany
    Drug Metab Dispos 29:1454-9. 2001
  7. ncbi Cambridge Healthtech Institute's 2nd Annual Conference on Pharmacogenomics Europe: presaging profits
    R Kerb
    EPIDAUROS Biotechnologie AG, AM Neuland, Bernried, Germany
    Pharmacogenomics 2:303-5. 2001
  8. ncbi Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene
    K Gellner
    EPIDAUROS Biotechnologie AG, Bernried, Germany
    Pharmacogenetics 11:111-21. 2001
  9. ncbi Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation
    R Sprenger
    Epidauros Biotechnology, Pharmacogenetics Laboratory, Bernried, Germany
    Pharmacogenetics 10:557-65. 2000
  10. ncbi Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
    S Hoffmeyer
    Epidauros Biotechnology, Pharmacogenetics Laboratory, Am Neuland 1, D 82347 Bernried, Germany
    Proc Natl Acad Sci U S A 97:3473-8. 2000

Collaborators

Detail Information

Publications10

  1. ncbi Recombinant antibody fragments and immunotoxin fusions for cancer therapy
    U Brinkmann
    Epidauros Biotechnology, Pharmacogenetics Laboratory, Bernried, Germany
    In Vivo 14:21-7. 2000
    ..Ongoing clinical trials provide examples where the promising preclinical data correlate with successful results in experimental cancer therapy...
  2. ncbi Polymorphisms in the ABC drug transporter gene MDR1
    U Brinkmann
    Epidauros Biotechnology, Pharmacogenetics Labs, Bernried, Germany
    Pharmacogenomics J 1:59-64. 2001
    ..Recently, functional genetic polymorphisms in the MDR1 gene have been identified which influence the distribution and bioavailability of PGP substrates...
  3. ncbi Recombinant immunotoxins for cancer therapy
    U Brinkmann
    Epidauros Biotechnology, Pharmacogenetics Lab, Bernried, FRG, Germany
    Expert Opin Biol Ther 1:693-702. 2001
    ..Ongoing clinical trials provide examples where the promising preclinical data correlate with successful results in experimental cancer therapy...
  4. ncbi ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2
    R Kerb
    Epidauros Biotechnology, Pharmacogenetics Laboratory, Am Neuland 1, D 82347 Bernried, Germany
    Pharmacogenomics 2:51-64. 2001
    ..An overview is provided of pharmacologically relevant genetic, structural and functional data as well as on hereditary polymorphisms, their phenotypical consequences and pharmacological implications...
  5. ncbi The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels
    R Kerb
    Epidauros Biotechnology AG, Pharmacogenetics Laboratory, Bernried, Germany
    Pharmacogenomics J 1:204-10. 2001
    ....
  6. ncbi Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4
    E Hustert
    EPIDAUROS Biotechnologie AG, Bernried, Germany
    Drug Metab Dispos 29:1454-9. 2001
    ..Thus, these natural PXR protein variants may play a role in the observed interindividual variability of CYP3A4 expression and may be involved in rare, atypical responses to drugs or altered sensitivities to carcinogens...
  7. ncbi Cambridge Healthtech Institute's 2nd Annual Conference on Pharmacogenomics Europe: presaging profits
    R Kerb
    EPIDAUROS Biotechnologie AG, AM Neuland, Bernried, Germany
    Pharmacogenomics 2:303-5. 2001
    ..The major strength of the meeting was the merging of scientists from many different disciplines, such as clinicians, pharmacologists, molecular biologists, engineers and bioinformatics experts, into one meeting...
  8. ncbi Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene
    K Gellner
    EPIDAUROS Biotechnologie AG, Bernried, Germany
    Pharmacogenetics 11:111-21. 2001
    ..This, in turn, will lead to a better optimization of therapies involving the numerous substrates of CYP3A proteins...
  9. ncbi Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation
    R Sprenger
    Epidauros Biotechnology, Pharmacogenetics Laboratory, Bernried, Germany
    Pharmacogenetics 10:557-65. 2000
    ..0001, anova)...
  10. ncbi Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
    S Hoffmeyer
    Epidauros Biotechnology, Pharmacogenetics Laboratory, Am Neuland 1, D 82347 Bernried, Germany
    Proc Natl Acad Sci U S A 97:3473-8. 2000
    ..Homozygosity for this variant was observed in 24% of our sample population (n = 188). This polymorphism is expected to affect the absorption and tissue concentrations of numerous other substrates of MDR-1...